Biohaven Pharma (BHVN) Q2 NURTEC ODT Sales Rise to $93M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Biohaven Pharmaceuticals (BHVN) Gains Following Sales Surge for Migraine Drug NURTEC ODT
July 7, 2021 11:36 AM EDTBiohaven Pharmaceutical (NYSE: BHVN) shares are gaining 11% following the announcement of preliminary Q2 results: net product revenue of NURTEC ODT (rimegepant) came in at $93M, increasing 119% Q/Q. Total prescriptions since the product launch exceeded 750,000 across 38,000 unique subscribers.
The results have far outpaced analysts' expectations consensus sales figures hovered around $50-55 million.
Commenting on the strong performance, the companys CCO, BJ... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $130 at Cowen on Nurtec Momentum
July 7, 2021 10:38 AM EDTCowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $130.00 (from $90.00) while maintaining an Outperform rating.
The analyst commented, "Preliminary Nurtec revenues reached $93MM in Q2, substantially above our and the Street's $55MM. Although we are unsure... More
